The BH3 ‐only protein NOXA is essential for apoptosis induction by BH3 ‐mimetics targeting BCL2 or BCL ‐ X L in DLBCL
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70192 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Nahide Yildirim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-bcl-2, bcl-X Protein, Apoptosis. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm-Sander Stiftung, Deutsche Krebshilfe, Else-Kröner Fresenius Stiftung.
Abstract (Originalsprache)
BCL2 inhibitors (BCL2i) have transformed the management of chronic lymphocytic leukaemia (CLL), but their use in more aggressive B‐cell malignancies such as diffuse large B‐Cell lymphoma (DLBCL) is complicated by the more heterogeneous nature of the disease. Successful responses are limited to a subset of patients, highlighting the need for robust biomarkers predicting sensitivity. Here, we investigated the underlying mechanisms of inherent resistance to the BCL2i ABT‐199 and BCL‐X L inhibitor A1331852, focusing on the roles of the principal pro‐apoptotic BH3‐only proteins NOXA and BIM. We show that NOXA deletion, but not BIM deletion, in BCL2 and BCL‐X L ‐dependent DLBCL cells both in vitro and in vivo resulted in a highly significant enhanced resistance to both BCL2i and BCL‐X L inhibitors. In contrast, NOXA deletion did not result in alteration of sensitivity to MCL1 inhibitors. NOXA loss was associated with increased stability and binding capacity of MCL1; binding of BIM to MCL1 was associated with resistance to ABT‐199. Resistance to BCL2i and BCL‐X L inhibitors was abrogated by suppression of MCL1 expression. In conclusion, we show that NOXA is essential for the effectiveness of BH3‐mimetics targeting BCL2/BCL‐X L ; in the absence of NOXA, BIM displaced from BCL2/BCL‐X L can be bound by MCL1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.
- The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
- German Cancer Consortium (DKTK) Partner Site Frankfurt/Mainz, a Partnership Between DKFZ and University Hospital Frankfurt, Frankfurt, Germany.
- University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe-University Frankfurt, Frankfurt, Germany.
ORCID-Profile: Martin J S Dyer, Meike Vogler
Förderung
- Wilhelm-Sander Stiftung
- Deutsche Krebshilfe
- Else-Kröner Fresenius Stiftung
- Scott Waudby Charitable Trust
Zitieren
APA
Yildirim, N., Anders, M., Smith, V. M., Jayne, S., Assmann, M., Jukes-Jones, R., Dyer, M. J. S., & Vogler, M. (2026). The BH3 ‐only protein NOXA is essential for apoptosis induction by BH3 ‐mimetics targeting BCL2 or BCL ‐ X L in DLBCL. British Journal of Haematology. https://doi.org/10.1111/bjh.70192
Vancouver
Yildirim N, Anders M, Smith VM, Jayne S, Assmann M, Jukes-Jones R, et al. The BH3 ‐only protein NOXA is essential for apoptosis induction by BH3 ‐mimetics targeting BCL2 or BCL ‐ X L in DLBCL. British Journal of Haematology. 2026. doi:10.1111/bjh.70192
BibTeX
@article{Yildirim2026,
author = {Yildirim, Nahide and Anders, Marius and Smith, Victoria M and Jayne, Sandrine and Assmann, Moritz and Jukes-Jones, Rebekah and Dyer, Martin J S and Vogler, Meike},
title = {The BH3 ‐only protein NOXA is essential for apoptosis induction by BH3 ‐mimetics targeting BCL2 or BCL ‐ X L in DLBCL},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70192}
}
EUVIMED